Polyplex of peptide-mannan and RNA for intranasal delivery of TGF-β siRNA in treatment of pulmonary fibrosis

Key Points

• Treatment with TGF-β siRNA shows improved efficacy in reducing fibrosis markers in lung tissue, indicating positive impact.
• Key evidence includes significant reduction in fibrosis markers by 40% in animal models, demonstrating potential effectiveness.
• The method includes intranasal delivery using a polyplex of peptide-mannan and RNA, optimizing transport to target tissue.
• Implications suggest a promising approach for pulmonary fibrosis treatment; further research is needed to confirm these findings.